{"id":"bendamustine-or-gemcitabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL487253","moleculeType":"Small molecule","molecularWeight":"358.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bendamustine is a nitrogen mustard derivative that cross-links DNA strands, preventing replication and transcription. Gemcitabine is a deoxycytidine analog that inhibits DNA synthesis by blocking ribonucleotide reductase and incorporating into the growing DNA chain, causing premature termination. Together, they provide complementary cytotoxic mechanisms targeting rapidly dividing cancer cells.","oneSentence":"This is a combination of two chemotherapy agents: bendamustine, which alkylates DNA and disrupts cell division, and gemcitabine, which inhibits ribonucleotide reductase and gets incorporated into DNA to cause chain termination.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:55.335Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (lymphoma, leukemia)"},{"name":"Solid tumors (under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT06522737","phase":"PHASE3","title":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","status":"RECRUITING","sponsor":"SecuraBio","startDate":"2025-05-19","conditions":"Lymphoma","enrollment":124},{"nctId":"NCT05300282","phase":"PHASE1, PHASE2","title":"Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2023-02-27","conditions":"Relapsed or Refractory Hodgkin's Lymphoma","enrollment":122},{"nctId":"NCT05508867","phase":"PHASE2","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-10-18","conditions":"Hodgkin Lymphoma","enrollment":203},{"nctId":"NCT04607772","phase":"PHASE1, PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT07059650","phase":"PHASE1, PHASE2","title":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2025-08-19","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":150},{"nctId":"NCT03739619","phase":"PHASE1, PHASE2","title":"Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-11-26","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT03593018","phase":"PHASE3","title":"Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2018-11-09","conditions":"Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma","enrollment":86},{"nctId":"NCT06170489","phase":"PHASE3","title":"A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-12-28","conditions":"Hodgkin Lymphoma","enrollment":185},{"nctId":"NCT03615664","phase":"PHASE2","title":"The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD","status":"COMPLETED","sponsor":"Polish Lymphoma Research Group","startDate":"2017-11-06","conditions":"Hodgkin's Lymphoma","enrollment":115},{"nctId":"NCT06761911","phase":"PHASE4","title":"BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Xiuhua Sun","startDate":"2024-12-31","conditions":"Hodgkin Lymphoma (Category)","enrollment":100},{"nctId":"NCT03997968","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cyteir Therapeutics, Inc.","startDate":"2019-10-09","conditions":"Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma","enrollment":169},{"nctId":"NCT06465446","phase":"PHASE3","title":"A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","startDate":"2024-06","conditions":"Classic Hodgkin Lymphoma","enrollment":202},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT05660993","phase":"PHASE2","title":"Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"National Research Center for Hematology, Russia","startDate":"2019-08-19","conditions":"Hodgkin Lymphoma","enrollment":50},{"nctId":"NCT02954406","phase":"PHASE1","title":"A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2017-03-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":43},{"nctId":"NCT01535924","phase":"PHASE1, PHASE2","title":"Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Beth Christian","startDate":"2012-02-09","conditions":"Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma","enrollment":26},{"nctId":"NCT04882163","phase":"PHASE1, PHASE2","title":"Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma","status":"WITHDRAWN","sponsor":"Celgene","startDate":"2021-10-10","conditions":"Lymphoma, B-Cell","enrollment":""},{"nctId":"NCT03259529","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL","status":"COMPLETED","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2017-03-27","conditions":"Diffuse Large B Cell Lymphoma","enrollment":30},{"nctId":"NCT02951156","phase":"PHASE3","title":"Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-12-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":29},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT01232556","phase":"PHASE3","title":"A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-04-04","conditions":"Lymphoma, Non-Hodgkin","enrollment":338}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bendamustine or gemcitabine","genericName":"Bendamustine or gemcitabine","companyName":"Shanghai Junshi Bioscience Co., Ltd.","companyId":"shanghai-junshi-bioscience-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of two chemotherapy agents: bendamustine, which alkylates DNA and disrupts cell division, and gemcitabine, which inhibits ribonucleotide reductase and gets incorporated into DNA to cause chain termination. Used for Hematologic malignancies (lymphoma, leukemia), Solid tumors (under investigation in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}